Five Doubly Unsaturated Metabolites of Valproic Acid in Urine and Plasma of Patients on Valproic Acid Therapy

By W. Kochen, H. P. Sprunck
Klinikum der Universität Heidelberg, Kinderklinik
B. Tauscher and M. Klemens
Organisch-Chemisches Institut der Universität Heidelberg

(Received June 20, 1983/January 30, 1984)

Summary: The urine and plasma of epileptic patients receiving therapeutic doses of valproic acid (2-propyl-pentanoic acid) was found to contain five doubly unsaturated metabolites of valproic acid, which were identified as their trimethylsilyl derivatives by GC/MS. A series of reference substances was synthesized but only two of them were identical with native metabolites: 2(2-propenyl)-4-pentenoic acid (= 4.4’-diene) and E-2-propyl-2.4-pentadienoic acid (E-2.4-diene). The mass-spectra of the five native metabolites are given. Preliminary quantitative data obtained from four groups of patients indicate increased formation of doubly unsaturated metabolites when valproic acid-induced side-effects are present, and in cases of fatal hepatic failure. The 4.4’-diene has hitherto been found only in fatal cases with hepatic injury. Quantitative data are presented as % of the sum of valproic acid plus all its detected metabolites.

Fünf zweifach ungesättigte Metabolide der Valproinsäure in Urin und Plasma von epileptischen Patienten unter Behandlung mit Valproinsäure


Introduction

Valproic acid (2-propyl-pentanoic acid) is a widely used antiepileptic drug extremely effective against absence and generalized tonic-clonic seizures (1). It was commonly believed to be relatively free from adverse side-effects. During recent years, however, it has been incriminated as the cause of severe, and in some instances fatal hepatic injuries (2). Throughout the world, a total of 68 fatal cases have been recognized (3). Early calculations revealed frequencies of 1:10000—1:20000 (4) and 1:50000 (5). The pathogenesis of this fatal hepatic failure is not understood and the first case in which valproic acid metabolism could be studied was published by Kochen et al. (6). The prominent feature in this patient was the...
abnormally increased formation of mono- and di-unsaturated metabolites of valproic acid. Therefore it seems necessary to further investigate this new group of doubly unsaturated metabolites, which we reported earlier (7).

There are substantial problems in the synthesis of doubly unsaturated derivatives of valproic acid, because the introduction of two double bonds results in 14 different stereoisomers. Moreover, if carbon 2 in valproic acid becomes chiral then an additional 4 enantiomers must be taken into consideration: Both stereoisomers of the 3.4'-diene form enantiomers (D- and L-2(2-propenyl)-3-trans-pentenoic acid and D- and L-2(2-propenyl)-3-cis-pentenoic acid).

In the case of the 3.3'-diene only 2(1-trans-propenyl)-3-cis-pentenoic acid may be expected to form enantiomers.

In the present work, we report the detection of a total of five doubly unsaturated metabolites of valproic acid in patients on valproic acid therapy. Preliminary quantitative data indicating the possible pathological importance of this new group of metabolites are also presented.

Methods and Materials

Valproic acid derivatives

The syntheses of doubly unsaturated valproic acid derivatives have been described by Klemens (8).

All these compounds have not been described in literature except the 4.4'-diene (9, 10).

2(2-Propenyl)-4-pentenoic acid (4.4'-diene) was obtained by malonic ester synthesis using allylbromide, followed by saponification and decarboxylation.

2(2-Propenyl)-3-pentenoic acid (3.4'-diene): Knoevenagel-reaction of propionaldehyde and diethylmalonate, alkylation of the propylidenedimethylmalonate with 1-bromopropane-2, saponification and decarboxylation.

2(2-Propenyl)-2-pentenoic acid (2.4'-diene): acylation of diethylmalonate with propionylchloride, alkylation with allylbromide, reduction by NaBH₄, decarboxylation, dehydration and saponification.

2-Propyl-2.4-pentadienoic acid (2.4'-diene) was obtained by a Wittig reaction with 2-bromoethylpentanoate and acrolein.

2(1-Propenyl)-2-pentenoic acid (2.3'-diene): nucleophilic acylation of 1-bromopropane with umgepoltem crotonaldehyde followed by saponification.

Mass-spectra of the synthetic diene compounds

The synthetic products were purified by common methods. The trimethylsilylesters of the acids were analysed by GC/MS.

Determination of valproic acid metabolites by GC/MS

Sample preparation

50–200 μl of the sample (urine, plasma etc.) were added to 200 μl of 0.5 mol/l NaH₂PO₄ buffer pH 5.0 containing 3 internal standards (1 μg each of di-n-butylacetate, phenylbutyric acid and C₁₈-alkane) and 20 μl glucuronidase/arylsulphatase (Serva, Heidelberg). After incubation of the mixture for 3 h at 37 °C the metabolites were extracted with ethyl acetate (3 times; 0.5 ml). The volume of the combined organic phases was reduced to about 20 μl (not to dryness!) under a stream of dry nitrogen. The acids were silylated with 10 μl N-methyl-trimethylsilyl-trifluoracetamide (MSTFA, Machery & Nagel, Düren).

Gas-chromatographic conditions

50 m capillary glass column SE-54 (Jaegi, Trogen, Switzerland), split 1:20, temperature programme 75 °C (10 min), 4 °C/min up to 200 °C, P. 1.2 bar (He). Mass-spectrometer DuPont 21-492 B, open interface combination, ionisation energy 70 eV, ion source temperature 250 °C, interface 210 °C.

Quantification

Valproic acid, its metabolites and the internal standards were mass-fragmentographically determined by means of M⁺ – 15 mass-ions. Calibration samples were prepared as above. Quantification of diene/3 and diene/4 was performed by using two other synthetic diene derivatives with identical intensities of m/z 197 and 122 as in the native metabolites.

Results

Synthetic diene compounds

GC/MS investigations demonstrated that the synthesized products consisted of mixtures of isomers, which we have numbered /1, /2, etc. according to their increasing retention time. The isomers were not isolated and the stereo-chemical structure remains unknown. Table 1 presents the mass-ions and their intensity in % base-peak. The most intensive mass above m/z 100 was selected for the base-peak; the fragments below m/z 90 were considered to be of minor importance, and were therefore ignored. In investigating new synthesies for diene compounds without a terminal double bond, we obtained a series of doubly unsaturated valproic acid derivatives which were characterized by GC/MS. Three of these (diene-S5, diene-S6, and diene-S7) are also listed in table 1.

Native diene metabolites

Synthetic hydroxylated valproic acid derivatives (hydroxylated in position 5, 4, 3 and 2) were added to control samples of urine and plasma, and the samples prepared for GC-analysis as described in methods. Mass-fragmentographic analysis of hydroxylated valproic acid derivatives did not generate detectable unsaturated derivatives, i.e. dehydration does not occur under the conditions used.

As an example figure 1 presents the mass-fragmentographic chromatogram of a urine sample from an epileptic and extremely dystrophic patient treated with valproic acid.
with valproic acid. The usual mono-ene metabolites 2-propyl-3-pentenoic acid (3-ene) and 2-propyl-2-pentenoic acid (Z- and E-2-ene) (see arrow 2, 3a and 3b), the oxidized metabolites (see arrow 8–12), and three doubly unsaturated metabolites E-2-propyl-2.4-pentadienoic acid (= E-2.4-diene, diene/1), diene/2, and diene/3 (see arrow 4–6) are all clearly demonstrated. Due to their low concentration it is usually impossible to detect them on the basis of the total ion current (TIC) alone, and especially diene/3 is often hidden in the overlapping urea peak. Removal of urea by urease before extraction remarkably facilitates the detection of diene/3. Mass-spectra of the diene metabolites were obtained from urine samples containing elevated amounts of the compounds concerned. The typical mass-fragmentographic ions of the trimethylsilyl derivatives are the molecular ion m/z 212 and the M−15 mass ion.

Most of the diene metabolites were characterized by their mass-spectra. The M−15 mass ion was determined at m/z 197.0945 (theoretical value 197.0998). In view of the higher retention time of this isomer we assume that it has the following structure: E-2-propyl-2.4-pentadienoic acid trimethylsilyl derivative.

### Tab. 1. Synthetic diene compounds of valproic acid and the EI mass-spectra of their trimethylsilyl derivatives. The most intense mass-ion above m/z 100 was taken as base-peak (100%). Mass-ions below m/z 90 were abandoned. For further details of dienes S5, S6 and S7 see text.

<table>
<thead>
<tr>
<th>Compound</th>
<th>m/z (% base-peak)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2(2-Propenyl)-4-pentenoic acid (4.4'-diene)</td>
<td>197 (100), 94 (64), 117 (37), 171 (34), 111 (23), 169 (20), 122 (15), 105 (8)</td>
</tr>
<tr>
<td>2(2-Propenyl)-3-pentenoic acid, 1st isomer (3.4'-diene/1)</td>
<td>197 (100), 155 (29), 81 (26), 171 (22), 94 (20), 169 (17), 170 (16), 117 (16), 212 (12), 156 (12), 111 (8), 122 (5), 157 (5)</td>
</tr>
<tr>
<td>2(2-Propenyl)-3-pentenoic acid, 2nd isomer (3.4'-diene/2)</td>
<td>171 (100), 197 (68), 117 (49), 156 (35), 95 (20), 125 (18), 129 (13), 111 (11), 112 (10), 212 (8), 155 (7), 143 (7), 122 (5), 118 (5)</td>
</tr>
<tr>
<td>Diene-S11: additional diene from synthesis of 3.4'-diene</td>
<td>197 (100), 212 (74), 122 (20), 96 (10), 123 (10), 183 (8), 167 (7), 156 (6), 107 (6), 110 (5)</td>
</tr>
<tr>
<td>2(2-Propenyl)-2-pentenoic acid, 1st isomer (2.4'-diene/1)</td>
<td>197 (100), 94 (50), 117 (34), 155 (30), 171 (28), 111 (22), 169 (17), 122 (16), 170 (14), 156 (14), 129 (11), 212 (11)</td>
</tr>
<tr>
<td>2(2-Propenyl)-2-pentenoic acid, 2nd isomer (2.4'-diene/2)</td>
<td>197 (100), 122 (73), 212 (70), 123 (39), 93 (22), 107 (17), 95 (17), 167 (17), 124 (11), 181 (10), 183 (9), 155 (5), 125 (5)</td>
</tr>
<tr>
<td>2-Propyl-2.4-pentadienoic acid, 1st isomer (2.4'-diene/1)</td>
<td>197 (100), 183 (97), 122 (79), 123 (35), 95 (23), 153 (9), 155 (8), 169 (7), 184 (7), 117 (6)</td>
</tr>
<tr>
<td>2-Propyl-2.4-pentadienoic acid, 2nd isomer (2.4'-diene/2)</td>
<td>122 (100), 197 (75), 123 (50), 183 (31), 212 (25), 196 (12), 107 (10), 181 (7), 167 (7), 155 (7), 111 (5), 169 (4)</td>
</tr>
<tr>
<td>2(1-Propenyl)-2-pentenoic acid, 1st isomer (2.3'-diene/1)</td>
<td>197 (100), 122 (45), 212 (40), 183 (40), 123 (30), 110 (13), 95 (12), 196 (10), 152 (10), 124 (10), 167 (8)</td>
</tr>
<tr>
<td>Diene-S5</td>
<td>212 (100), 197 (96), 122 (88), 93 (22), 167 (18), 123 (15), 181 (14), 95 (13), 107 (10), 101 (8), 115 (6), 173 (6), 117 (5), 112 (4)</td>
</tr>
<tr>
<td>Diene-S6</td>
<td>122 (100), 197 (89), 212 (85), 147 (42), 95 (35), 140 (21), 167 (14), 181 (9), 107 (8), 169 (8), 157 (7), 111 (6), 131 (6), 117 (4)</td>
</tr>
<tr>
<td>Diene-S7</td>
<td>197 (100), 212 (40), 122 (31), 117 (15), 129 (14), 133 (11), 123 (9), 183 (6), 156 (6), 184 (5), 169 (5)</td>
</tr>
</tbody>
</table>
Valproic acid metabolites:
1) 2-propyl-4-pentenoic acid (4-ene),
2) 2-propyl-3-pentenoic acid (3-ene, sum of cis and trans),
3a and 3b) 2-propyl-2-pentenoic acid ((Z)2-ene and (E)2-ene),
4) E-2-propyl-2,4-pentadienoic acid (E-2,4-diene),
5) diene/2,
6) diene/3,
7) diene/4,
8a and 8b) diastereomers of 2-propyl-4-hydroxy-pentanoic acid,
9) both diastereomers of 2-propyl-3-hydroxy-pentanoic acid,
10a and 10b) 2-propyl-3-hydroxy-2-pentenoic acid (3-ketoenol),
11) 2-propyl-5-hydroxy-pentanoic acid,
12) 2-propylglutaric acid,
13) urea and other constituents.
- Internal standards (i.st.):
14) di-n-butylacetic acid,
15) phenylbutyric acid,
16) C19-alkane.
- Other acids:
17) 3-hydroxy-2-ethyl-propionic acid,
18) benzoic acid,
19) 3-hydroxy-isovaleric acid,
20) lactic acid.
GC-conditions see text.

Fig. 1. GC/MS chromatogram of a hydrolysed urine sample of a patient treated with valproic acid (VPA). Mass-ions are given in the 3 channels, attenuation on the left side of each channel. Typical mass-ions of the metabolites as trimethylsilyl derivatives are indicated by arrows.
TIC = total ion current.
The mass-spectrum of diene/2 trimethylsilyl derivative (see arrow 5 in fig. 1) is given in figure 3 and is likewise characterized by the base-peak of m/z 122 as in E-2-propyl-2.4-pentadienoic acid trimethylsilyl derivative (= diene/1). Exactly defined reference compounds are not available for either diene/2 or the diene metabolites discussed in the following. As figure 8 indicates all defined synthetic diene compounds have shorter retention times. Only the synthetic products, diene-S5, diene-S6, and diene-S7 were found in small amounts as by-products in the synthesis of the 2.3'-diene and 3.3'-diene. Their mass-spectrometric data indicating a diene structure are therefore also listed in table 1. The positions of the two double bonds in these three unsaturated products were not elucidated.

In spite of the identical retention time of diene/2 and the synthetic product diene-S5 their mass-spectra differ with respect to the relative intensities of the typical mass-ions.

The mass-spectrum of diene/3 trimethylsilyl derivative (fig. 4) is also in accordance with the presence of a doubly unsaturated metabolite as confirmed by high-resolution of the molecular ion (found m/z 212.1195, theoretical value 212.1232).

The following two doubly unsaturated metabolites were detected and identified in fatal cases (6, 12), whereas they are unknown in patients without complications. Identification of 2(2-propenyl)-4-pentenoic acid (4.4'-diene) was possible only because the samples of the patient concerned (6) contained a very low concentration of valproic acid. As demonstrated in figure 5, the trimethylsilyl derivatives of the synthetic 4.4'-diene, 4-ene and valproic acid are eluted very close together under the gas chromatographic conditions used, so that in the presence of an excess of valproic acid it is difficult to detect these
two metabolites. The mass-spectrum of the native 4.4'-diene trimethylsilyl derivative is given in figure 6 and agrees well with that of the synthetic product. The relative intensity of m/z 122 amounts only to about 15% and the molecular ion m/z 212 is not higher than 10% of the base-peak m/z 197, whose exact mass was determined at 197.1092 (theoretical value 197.0998).

The 4.4'-diene is not present in the sample shown in figure 1, but the 4-ene (arrow 1) is present in more than trace amounts. This metabolite is not normally detectable in urine or plasma, and its existence was confirmed by the characteristic mass-ions m/z 172 and 185 and by the addition of the authentic reference compound. The mass-spectrum of the 4-ene has been published in l.c. (6).

The last of the five diene metabolites has the highest retention time and is termed diene/4. As in the case of diene/3, it may be overlapped by urea. The molecular ion was determined at m/z 212.1300. The typical mass-ions indicate again a doubly unsaturated metabolite, although an authentic reference substance is still lacking (mass-spectrum fig. 7). In figure 1 traces of diene/4 were also detected by recording m/z 122.

A comparison of the retention indices of both the synthetic and the native diene compounds is given in figure 8. The synthetic products, diene-S5, diene-S6 and diene-S7 are not defined in respect to the position of the two double bonds and they are listed only on the basis of their increasing retention times, which are in the same order as those of the native diene-metabolites, diene/2, diene/3, and diene/4. For analytical purposes the exact relative retention times of the trimethylsilyl derivatives of valproic acid, the five diene metabolites, and the mono-ene metabolites are summarized in table 2. The gas chromatographic peaks are more or less contaminated by

Fig. 4. Mass-spectrum of native diene/3 trimethylsilyl derivative.

Fig. 5. GC/MS chromatogram of synthetic valproic acid (VPA), 2-propyl-4-pentenoic acid (4-ene), and 2(2-propenyl)-4-pentenoic acid, (4.4'-diene) as trimethylsilyl derivatives.

Fig. 6. Mass-spectrum of native 2(2-propenyl)-4-pentenoic acid (4.4'-diene) trimethylsilyl derivative.

other urinary acidic constituents which, depending on their concentration, may completely overlap these valproic acid metabolites. The commonly found contamination products are also listed in table 2.

Tab. 2. Trimethylsilyl derivatives of the mono-ene- and diene metabolites of valproic acid: retention times (R<sub>t</sub>) are related to the internal standards, di-n-butylacetic acid trimethylsilyl derivative, phenylbutyric acid trimethylsilyl derivative, and C<sub>18</sub>-alkane. The contamination products listed are usually observed together with the metabolites in the urinary samples under the GC-conditions used (see method); TMS = trimethylsilyl derivative.

<table>
<thead>
<tr>
<th>Compound</th>
<th>R&lt;sub&gt;t&lt;/sub&gt;</th>
<th>Contamination by</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4'-diene</td>
<td>0.679/0.529/0.395</td>
<td>Overlapped by valproic acid</td>
</tr>
<tr>
<td>4-ene</td>
<td>0.687/0.535/0.400</td>
<td>Cresol TMS, 3-hydroxy-propionic acid TMS</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>0.698/0.545/0.405</td>
<td>3-Hydroxy-n-butric acid TMS</td>
</tr>
<tr>
<td>3-ene</td>
<td>0.712/0.554/0.414</td>
<td>2-Hydroxy-3-methyl-butric acid TMS</td>
</tr>
<tr>
<td>(Z) 2-ene</td>
<td>0.727/0.566/0.423</td>
<td>3-Hydroxy-isovaleric acid TMS</td>
</tr>
<tr>
<td>(E) 2-ene</td>
<td>0.809/0.650/0.471</td>
<td>(En-C&lt;sub&gt;3&lt;/sub&gt;-carboxylic acid)</td>
</tr>
<tr>
<td>E-2,4-diene</td>
<td>0.838/0.655/0.490</td>
<td>2-Ethyl-3-hydroxy-propionic acid TMS</td>
</tr>
<tr>
<td>diene/2</td>
<td>0.852/0.667/0.500</td>
<td>Urea TMS</td>
</tr>
<tr>
<td>diene/3</td>
<td>0.914/0.714/0.534</td>
<td>(Urea TMS), PO&lt;sub&gt;4&lt;/sub&gt; TMS</td>
</tr>
<tr>
<td>diene/4</td>
<td>0.940/0.736/0.552</td>
<td></td>
</tr>
</tbody>
</table>

Tab. 3. Concentration of diene metabolites of valproic acid in patients on valproic acid therapy. Values are given in % of the sum valproic acid plus all detected and quantified metabolites (= 100%). These percentages have proved to be more informative than the absolute quantitative data of the single metabolites. Besides

Concentration of the diene metabolites in patients on valproic acid therapy

Preliminary quantitative results for diene metabolites found in four groups of patients (adults without side-effects, children with reversible side-effects such as vomiting, drowsiness, anorexia etc, one fatal case with hepatic failure (6), and children without complications in therapy) are given in table 3 in % of the sum of valproic acid plus all detected and quantified metabolites (= 100%). These percentages have proved to be more informative than the absolute quantitative data of the single metabolites. Besides
the diene metabolites, the following metabolites are included: E-2-ene and Z-2-ene, cis-3-ene and trans-3-ene, 4-ene, 2-propyl-3-hydroxypentanoic acid, 2-propyl-3-oxopentanoic acid, 2-propyl-4-hydroxypentanoic acid, 2-propyl-5-hydroxypentanoic acid and 2-propylglutaric acid. It is evident that both the number and the concentration of the single diene metabolites are increased if clinical side-effects are present. Drastically enhanced amounts were found in a case with fatal hepatic failure (6). Similar results were obtained in 4 other fatal cases, although the concentrations of the diene metabolites in plasma and urine were not so greatly elevated as in the patient cited, and the metabolic patterns were slightly different (12).

E-2,4-diene, diene/2, and diene/3 may be regarded as normal metabolic products, and the last one is always the most prominent doubly unsaturated metabolite. E-2,4-diene is sometimes missing, and when present, its concentration is always very low in normal patients. In contrast, the 4,4'-diene is thought to be abnormal due to its complete absence from children and adults treated without complications. Diene/4 was sporadically observed only in adults, and its enhanced formation in the presence of side-effects and hepatotoxicity qualified this metabolite as possibly toxic.

Discussion

So far, we have detected a total of 5 doubly unsaturated metabolites of valproic acid. There are numerous possible isomers of these diene metabolites, which cannot be reliably differentiated and characterized by mass-spectrometry. To ensure the correct assignment of the two double bond positions, we therefore synthesized a series of doubly unsaturated derivatives of valproic acid (8). Only two of these synthetic compounds were found to be identical with native metabolites: 2(2-propenyl)-4-pentenoic acid (4,4'-diene) and E-2-propyl-2,4-pentadienoic acid (E-2,4-diene). The three other native diene metabolites are still non-defined with respect to the position and stereochemistry of the two double bonds. They are therefore termed diene/2, diene/3, and diene/4. However, their exact structures may be inferred from figure 8, and these are illustrated in the metabolic scheme in figure 9. All possible diene derivatives containing a terminal double bond have been synthesized and the retention times of these compounds are smaller than those of the native metabolites, diene/2, diene/3 and diene/4.

Some of the synthetic products containing a terminal double bond have the same retention time as the metabolic products, i.e. 4-ene, 4,4'-diene, and E-2,4-diene. Furthermore, it may be concluded from figure 8, that

a) the two double bonds in the native diene/2, diene/3, and diene/4 metabolites are distributed in both carbon chains,

b) the possibility of a terminal double bond in these three metabolites can be excluded, and

c) only 3,3'-diene isomers (3-trans/3'-cis, 3-cis/3'-cis, 3-trans/3'-trans) or 2,3'-diene isomers (2-trans/3'-trans, 2-cis/3'-cis, 2-cis/3'-trans, 2-trans/3'-cis) may be predicted.

This means that one double bond must be localized in 3, 4 position of the metabolites diene/2, diene/3 and diene/4. A shift of the terminal double bond to the inner tertiary carbon atom is accompanied by an increase in retention time (see fig. 8). Therefore, the structure of diene/4 and also of diene/3 is assumed to be rather a 2,3'-diene than a 3,3'-diene. Since the 2-ene is the main metabolite of the mono-ene group, its function as a precursor is more plausible than that of the 3,ene, normally only of minor importance. Consequently, diene/2 might be assigned a 3,3'-diene structure with the 3-ene as precursor.

The formation of the E-2,4-diene is unusual in so far as the second double bond is introduced into the propenyl and not into the propyl group. In this connection, it should be noted that 2,4-pentadienoic acid is formed metabolically from 4-pentenoic acid (13).

The metabolic pattern of valproic acid metabolism in fatal hepatic failure is characterized by an increased formation of doubly unsaturated metabolites as exemplified in a patient (see tab. 3) (6). The 4,4'-diene is considered to be an abnormal metabolite, which is never found in patients without severe complications. Its formation seems to be always accompanied by the 4-ene, which may also be sporadically observed in normal patients (but not more than 0.05%). The toxic effects of the 4-ene are thought to be analogous to the features of Reye's syndrome induced in rats by 4-pentenoic acid (14). As the 2-ene (main metabolite of the mono-ene group) and the 3-ene as well as the E-2,4-diene, diene/2, and diene/3 (main metabolite of the diene group) are normal and almost obligatory metabolites, the distinct appearance of the 4,4'-diene, the 4-ene, and the diene/4 in fatal hepatic damage (6, 12) may indicate a metabolite aberration, the cause of which is still unknown. The percentage distribution of the unsaturated metabolites was not unique in the fatal cases. Reversible valproic acid-induced side-effects (drowsiness,
dicative of a disturbed metabolic situation, if its urinary concentration is above the upper limit of 3% (valproic acid plus all found metabolites = 100%) (12). In addition, both the 4-ene and the 4.4'-diene are an indication that valproic acid treatment should be discontinued. One group of patients has been identified, which is particularly at risk; these are strongly retarded children with intractable epilepsy months after onset of valproic acid therapy. On rare occasions, valproic acid may initiate a type of liver failure that almost always leads to the death of the patient. The presence of side-effects associated with clinical signs of liver or pancreatic dysfunction, together with the appearance of the 4-ene, and the 4.4'-diene, and increased excretion of the diene/3 are an indication that valproic acid treatment should be discontinued. It is very difficult to decide when valproic acid therapy should be discontinued, because conventional liver function tests do not seem to predict hepatotoxicity. On rare occasions, valproic acid may initiate a type of liver failure that almost always leads to the death of the patient. The presence of side-effects associated with clinical signs of liver or pancreatic dysfunction, together with the appearance of the 4-ene, and the 4.4'-diene, and increased excretion of the diene/3 are an indication that valproic acid treatment should be discontinued. One group of patients has been identified, which is particularly at risk; these are strongly retarded children with intractable epilepsy on multiple antiepileptic drug therapy. Attention is imperative especially during the first 6 months after onset of valproic acid therapy.

References


Prof. Dr. W. Kochen
Klinikum der Universität Heidelberg
Kinderklinik
Im Neuenheimer Feld 150
D-6900 Heidelberg
